02591.HK
Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.40
+3.98%Margins
Gross margin
76.0%
EBITDA margin
-210.9%
EBIT margin
-219.5%
Net margin
-218.0%
FCF margin
-239.9%
-34.9%
Return on equity
-25.3%
Return on assets
-30.3%
Return on invested capital
0.11x
Asset turnover
-HKD 405.3M
Cash from operations
HKD 2.73
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026